Doctors and industry call on NHS to sustain medicines researchBMJ 2011; 342 doi: http://dx.doi.org/10.1136/bmj.d896 (Published 09 February 2011) Cite this as: BMJ 2011;342:d896
- Trish Groves
Doctors in the NHS need to engage more actively with drug studies if the UK is to remain one of the world’s most successful centres for research, say senior figures from medicine and industry.
Patrick Vallance, senior vice president of medicines discovery and development at GlaxoSmithKline, told a conference at the Royal College of Physicians, London, that the biggest question now for drug companies is “Is anyone going to buy this drug?”
Dr Vallance argued that the “blockbuster” model of drug development is unsustainable, and that new drugs will not be reimbursed in healthcare unless they are innovative and sufficiently differentiated from other treatments. Increasingly, companies will have to show real value to purchasers through effectiveness trials and database studies in clinical practice.
Dr Vallance warned that these studies …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial